Brexanolone, zuranolone and related neurosteroid GABA A receptor positive allosteric modulators for postnatal depression.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 40562419 · doi:10.1002/14651858.CD014624.pub2
What was done
A Cochrane systematic review and meta-analysis searched multiple databases (CENTRAL, MEDLINE, Embase, PsycINFO, trials registries) through January 2024 for randomized controlled trials (RCTs) evaluating neurosteroid GABAA receptor positive allosteric modulators (brexanolone, zuranolone, ganaxolone) in women with depression within 12 months postpartum. Comparators included placebo, active treatments, or treatment as usual. Primary outcomes were depression response, remission, and adverse events; secondary outcomes included depression severity (HAMD-17), treatment acceptability (study dropout), maternal functioning, and quality of life. Certainty was rated using GRADE.
What was found
Six RCTs were included (674 women, all US-based, all placebo-controlled). For intravenous modulators vs. placebo at 30 days: no clear difference was observed in depression response (risk ratio [RR] 1.24, 95% CI 0.74 to 2.06; I² = 78%; 3 studies, 267 women; low certainty), remission (RR 1.18, 95% CI 0.59 to 2.38; I² = 73%; 3 studies, 267 women; low certainty), or maternal adverse events (RR 1.02, 95% CI 0.71 to 1.48; I² = 46%; 4 studies, 325 women; moderate certainty), with lower acceptability leading to dropout (RR 2.77, 95% CI 1.22 to 6.26; 3 studies, 267 women; moderate certainty). For oral zuranolone vs. placebo at 45 days: zuranolone improved response (RR 1.26, 95% CI 1.03 to 1.55; I² = 13%; 2 studies, 349 women; moderate certainty), remission (RR 1.65, 95% CI 1.22 to 2.22; I² = 0%; 2 studies, 349 women; moderate certainty), and depression severity (mean difference [MD] -3.79 points on HAMD-17, 95% CI -5.60 to -1.97; 2 studies, 349 women; moderate certainty), but increased maternal adverse events, primarily somnolence (RR 1.24, 95% CI 1.03 to 1.48; I² = 0%; 2 studies, 349 women; moderate certainty).
Why it matters
This review establishes moderate-certainty evidence that oral zuranolone offers short-term benefits in depression response and remission over placebo, balanced against higher adverse event rates, whereas evidence for intravenous formulations remains uncertain.
Limits
The total evidence base is small (6 trials, 674 women total; trial sample sizes 21 to 196) and geographically restricted to the United States. All included trials were sponsored with substantial design and operational involvement by the manufacturing pharmaceutical companies. All comparators were placebo, leaving head-to-head efficacy against standard antidepressants or psychological interventions unmeasured. High heterogeneity affected intravenous trial outcomes, and no studies evaluated quality of life or infant-specific outcomes.
Cited by
- supports A pharmaceutical was developed to treat postpartum depression by restoring allopregnanolone signaling.